Entrada Therapeutics (TRDA)
(Delayed Data from NSDQ)
$14.72 USD
-0.31 (-2.06%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $14.70 -0.02 (-0.14%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for Entrada Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -6.69 | -94.62 | -51.16 | -26.52 | 0.00 |
Depreciation/Amortization & Depletion | -2.94 | 2.05 | 1.12 | 0.33 | 0.00 |
Net Change from Assets/Liabilities | 124.33 | -18.76 | -3.42 | 0.28 | 0.00 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 25.10 | 17.55 | 2.60 | 0.35 | 0.00 |
Net Cash From Operating Activities | 139.80 | -93.79 | -50.86 | -25.57 | 0.00 |
Property & Equipment | -5.61 | -2.89 | -4.58 | -2.32 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -132.78 | -145.76 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -138.40 | -148.65 | -4.58 | -2.32 | 0.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 21.04 | 0.48 | 307.46 | 50.09 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 21.04 | 0.48 | 307.46 | 50.09 | 0.00 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 22.45 | -241.96 | 252.02 | 22.20 | 0.00 |
Cash at Beginning of Period | 49.11 | 291.06 | 39.05 | 16.84 | 0.00 |
Cash at End of Period | 71.55 | 49.11 | 291.06 | 39.05 | 0.00 |
Diluted Net EPS | -0.20 | -3.02 | -8.16 | -24.00 | NA |
Fiscal Year End for Entrada Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 78.53 | 23.50 | -6.69 | 2.86 | -32.60 |
Depreciation/Amortization & Depletion | -2.45 | -1.10 | -2.94 | -1.68 | -0.66 |
Net Change from Assets/Liabilities | -75.22 | -54.18 | 124.33 | 122.22 | 188.81 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 13.46 | 6.27 | 25.10 | 20.42 | 12.76 |
Net Cash From Operating Activities | 14.31 | -25.52 | 139.80 | 143.82 | 168.31 |
Property & Equipment | -1.88 | -0.84 | -5.61 | -4.64 | -3.19 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 3.65 | 26.99 | -132.78 | -152.80 | -150.51 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 1.76 | 26.15 | -138.40 | -157.44 | -153.70 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 101.57 | 0.21 | 21.04 | 20.35 | 19.98 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 101.57 | 0.21 | 21.04 | 20.35 | 19.98 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 117.65 | 0.83 | 22.45 | 6.73 | 34.59 |
Cash at Beginning of Period | 71.55 | 71.55 | 49.11 | 49.11 | 49.11 |
Cash at End of Period | 189.20 | 72.39 | 71.55 | 55.83 | 83.69 |
Diluted Net EPS | 1.55 | 0.68 | -0.23 | 1.02 | -0.78 |